摘要
目的:评价复方丹参滴丸联合化疗治疗中晚期肝癌疗效及毒副反应。方法:96例中晚期肝癌患者随机分为A,B两组,A组(49例)采用复方丹参滴丸加化疗,B组(47例)采用单纯化疗。结果:A,B两组的有效率(CR+PR)分别为69.4%和61.7%(P>0.05),A,B两组的临床获益率(CR+PR+SD)分别为89.8%和70.2%(P<0.05),A组治疗后T淋巴细胞亚群中的CD4/CD8:比值有明显提高(P<0.05),而B组治疗前后无明显变化(P>0.05),生存质量A组高于B组(P<0.05),恶心呕吐,黏膜炎,腹泻,心脏毒性及白细胞减少B组高于A组(P<0.05)。结论:复方丹参滴丸联合化疗治疗肝癌能提高患者的治疗临床获益率、改善生存质量、减轻化疗某些不良反应和提高患者的免疫功能,值得进一步研究和使用。
Objective： To observe the efficacy and toxicity profile of Composite Salviae Dropping Pill plus chemotherapy for ad- vanced hepatocellular Carcinoma. Methods： 96 patients with advanced hepatocellular Carcinoma, were randomly divided to receive chemotherapy combined with Composite Salviae Dropping Pill （group A, 49 cases）or only chemotherapy （group B, 47 cases）. The efficacy, quality of llfe, toxicity profile were observe. Results ： The objective response rate （ CR ＋ PR） was 69.4% in group A, compared to 61.7 % in group B （ P 〉 0.05 ）, the clinical benefit response rate （ CR ＋ PR ＋ SD） was 89.8% in group A, compared to 70. 2% in group B（ P 〈0.05 ） ,the level of CDJCDs was significantly increased in group A,whereas no change was found in group B, quality of life in group A was higher than that in group B （ P 〈 0.05 ）, nausea, vomiting, mucitis ,diarrhea, cardiac toxicity, Leukopenia in group B were more serious than those in group A （ P 〈 0. 05）. Conclusion： Composite Salviae Dropping Pill giving a satisfactory clinical benefit response rate, decreasing side effects of chemotherapy, improving quality of the patients with hepatocellular Carcinoma and enhancing the immunofunctions of the patients with hepatocellular Carcinoma treated with chemotherapy, Composite Salviae Dropping Pill was worthy of clinical, administration.
出处
《中医药学刊》
2006年第1期186-188,共3页
Study Journal of Traditional Chinese Medicine
关键词
肝癌
复方丹参滴丸
化学疗法
hepatocellular carcinoma
composite salviae droping pill
chemotherapy
